Tecentriq is an immunotherapy drug that stimulates the body’s immune system to detect and attack cancer cells.
Patients with or without a tumor protein called PD-L1, which typically makes people more receptive to immunotherapy treatments, can use Tecentriq, according to Reuters.
The FDA based the approval on the results of a recent late-stage clinical trial showing patients taking Tecentriq lived, on average, 4.2 months longer than those treated with chemotherapy.
More articles on supply chain:
Tenn. high school opens medical device machinery lab
Sen. Blumenthal urges DOJ to reject Mylan settlement
TPC names ROi preferred supply chain partner: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
